AR047749A1 - Composicion cristalina que contiene escitalopram - Google Patents

Composicion cristalina que contiene escitalopram

Info

Publication number
AR047749A1
AR047749A1 ARP050100683A ARP050100683A AR047749A1 AR 047749 A1 AR047749 A1 AR 047749A1 AR P050100683 A ARP050100683 A AR P050100683A AR P050100683 A ARP050100683 A AR P050100683A AR 047749 A1 AR047749 A1 AR 047749A1
Authority
AR
Argentina
Prior art keywords
escitalopram
particles
composition containing
crystal composition
escitalopram oxalate
Prior art date
Application number
ARP050100683A
Other languages
English (en)
Spanish (es)
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of AR047749A1 publication Critical patent/AR047749A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
ARP050100683A 2004-03-05 2005-02-24 Composicion cristalina que contiene escitalopram AR047749A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA200400382 2004-03-05

Publications (1)

Publication Number Publication Date
AR047749A1 true AR047749A1 (es) 2006-02-15

Family

ID=36607154

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050100683A AR047749A1 (es) 2004-03-05 2005-02-24 Composicion cristalina que contiene escitalopram

Country Status (9)

Country Link
KR (1) KR20060126587A (zh)
CN (3) CN101492436A (zh)
AR (1) AR047749A1 (zh)
IL (1) IL177504A0 (zh)
MY (1) MY142756A (zh)
PE (1) PE20051162A1 (zh)
SG (1) SG159504A1 (zh)
TW (1) TW200605916A (zh)
ZA (1) ZA200607382B (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114763343A (zh) * 2021-01-14 2022-07-19 浙江华海药业股份有限公司 一种西酞普兰或s-西酞普兰的纯化方法
CN113663356B (zh) * 2021-08-23 2022-09-23 广西埃索凯新材料科技有限公司 一种应用于硫酸锰生产的结晶除杂监控系统

Also Published As

Publication number Publication date
IL177504A0 (en) 2006-12-10
MY142756A (en) 2010-12-31
ZA200607382B (en) 2008-05-28
PE20051162A1 (es) 2006-01-16
CN101492435A (zh) 2009-07-29
CN101492436A (zh) 2009-07-29
SG159504A1 (en) 2010-03-30
CN1925844A (zh) 2007-03-07
TW200605916A (en) 2006-02-16
KR20060126587A (ko) 2006-12-07

Similar Documents

Publication Publication Date Title
BRPI0508769A (pt) forma de dosagem resistente a adulteração compreendendo um adsorvente e um agente adverso
ATE530577T1 (de) Epha2 agonistische monoklonale antikörper und deren anwendungsverfahren
EP2520311A3 (en) Method of treating hemolytic disease
MA33044B1 (fr) Composition pharmaceutique contenant des derives de glucopyranosyl diphenylmethane, sa forme posologique galenique, son procede de preparation et ses utilisations pour une regulation glycemique amelioree chez un patient
ES2523660T3 (es) Composición para un material de electrodo, utilización de la misma y procedimiento para producir una célula solar
JP2005507881A5 (zh)
MXPA02007117A (es) Composiciones para suministrar un antagonista de cortisol..
WO2007143607A3 (en) Method of treating atrophic vaginitis
WO2009147402A3 (en) Compositions comprising honey and a super- absorbent material
AR109263A2 (es) Composición que comprende moxidectina
CY1111369T1 (el) Φαρμακευτικη συνθεση που περιλαμβανει 3-(3-διμεθυλαμινο-1-αιθυλ-2-μεθυλ-προπυλ)-φαινολη και παρακεταμολη
MX2010002926A (es) Moduladores de tieno y furo-pirimidina del receptor h4 de histamina.
WO2005023193A3 (en) Methods of treating endometriosis
TW200501965A (en) Highly pure fondaparinux sodium composition,process for preparing said composition and pharmaceutical compositions containing it as active principle
WO2005051307A3 (en) Epha2 agonistic monoclonal antibodies and methods of use thereof
WO2010019611A3 (en) Bridged polycyclic compound based compositions for topical and oral applications
SE0200895D0 (sv) New pharmaceutical composition
WO2006041843A3 (en) Pharmaceutical dosage form comprising meloxicam
BR0307518A (pt) Composição farmacêutica
AR047749A1 (es) Composicion cristalina que contiene escitalopram
WO2006048261A3 (en) Oral solid dosage forms containing a low dose of estradiol
EA200601641A1 (ru) Кристаллическая композиция, содержащая оксалат эсциталопрама
BRPI0415571A (pt) composições de limpeza
UY28789A1 (es) Composición cristalina que contiene escitalopram
DE50207110D1 (de) Kombinationspräparat zur behandlung des diabetes mellitus

Legal Events

Date Code Title Description
FA Abandonment or withdrawal